3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1
2
Phase NA
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
3
Lymphoma, T-Cell
2
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Immunoblastic Lymphadenopathy
1
Interventions
Doxorubicin
3
10-propargyl-10-deazaaminopterin
3
Vincristine
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Gemcitabine
2
Drug Therapy
2
Cyclophosphamide
2
Alemtuzumab
2
romidepsin
1
cc-486
1
belinostat
1
Vitamin B 12
1
Stem Cell Transplantation
1
Standard of Care
1
Specimen Handling
1
Prednisone
1
Practice Guidelines as Topic
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Hematopoietic Stem Cell Mobilization
1
Folic Acid
1
Etoposide
1
Cytarabine
1
Cladribine
1
Carmustine
1
Busulfan
1
Brentuximab Vedotin
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell
×
Alemtuzumab
×
Clear all
NCT00646854
2019-03-01
ACT-1
University of Aarhus
Phase 3
Completed
136 enrolled
NCT00725231
2012-05-07
A-CHOP-14
University of Göttingen
Phase 3
Unknown
274 enrolled